Zanidatamab — Drug Intelligence | 11 EU Trials

Filter these 11 trials by condition, phase, country and more.

Open in Search →

11 Registered trials

7 Recruiting

3 Completed trials

5 Sponsors

16 Countries

Phase III

Phase II

Phase I/II

Phase III: 4 Phase II: 5 Phase I/II: 2

Oversight events:

2 temporary halts across 1 trial

View oversight register →

Indications tested

Breast cancer 4 Breast cancer metastatic 2 HER2 mutant non-small cell lung cancer 1 HER2 protein overexpression 1 Ovarian cancer 1 Colorectal cancer 1 Head and neck cancer 1 HER2 positive endometrial cancer 1 Oesophageal adenocarcinoma 1 Breast cancer stage III 1 HER2 positive colorectal cancer 1 Non-small cell lung cancer 1

Sponsors using this IMP

Jazz Pharmaceuticals Ireland Limited 6 Unicancer 2 Boehringer Ingelheim International GmbH 1 Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH 1 Medica Scientia Innovation Research S.L. 1

All trials

11 total

PHASE IB/II STUDY TO EVALUATE SAFETY AND PRELIMINARY EFFICACY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB AND CHEMOTHERAPY (CAPECITABINE OR… Pending

2025-524613-89-00 Phase I/II 1 country Medica Scientia Innovation Research S.L.
A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants wit… Recruiting

2025-523204-68-00 Phase II 3 countries Jazz Pharmaceuticals Ireland Limited
Beamion BCGC-1: A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps … Recruiting

2023-509566-38-00 Phase I/II 5 countries Boehringer Ingelheim International GmbH
A Phase 2 study of zanidatamab in patients with HER2-expressing tumors Recruiting

2024-516551-41-00 Phase II 1 country Jazz Pharmaceuticals Ireland Limited
ZANGEA – Phase II Study of Zanidatamab in Combination with Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesopha… Recruiting

2025-522718-22-00 Phase II 1 country Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
Clinical trial evaluating the activity of zanidatamab for the treatment of patients with solid tumors with an alteration of the HER2 gene Recruiting

2025-522169-31-00 Phase II 1 country Unicancer
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys… Recruiting

2023-508960-31-00 Phase III 8 countries Jazz Pharmaceuticals Ireland Limited
Personalized medicine for advanced biliary cancer patients Recruiting

2023-508100-38-00 Phase III 2 countries Unicancer
An open-label randomized trial of zanidatamab for advanced HER2positive biliary tract cancer Ended

2023-508219-21-00 Phase III 10 countries Jazz Pharmaceuticals Ireland Limited
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gas… Ended

2023-510319-20-00 Phase III 12 countries Jazz Pharmaceuticals Ireland Limited
Study to evaluate the safety and tolerability of ZW25 in combination with palbociclib plus fulvestrant Ended

2023-508135-30-00 Phase II 1 country Jazz Pharmaceuticals Ireland Limited

Showing 1–11 of 11 trials

← All drugs A–Z